---
schema_version: "secwatch.filing_event.v1"
accession: "0001599298-26-000092"
form_type: "8-K"
ticker: "SMMT"
cik: "0001599298"
company_name: "Summit Therapeutics Inc."
filed_at: "2026-11-16T11:08:15+00:00"
generated_at: "2026-11-16T11:15:47.518230+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.92
calibrated_materiality_score: 0.92
confidence: "high"
source: SEC EDGAR
---

# FDA issues Complete Response Letter for Summit's ivonescimab BLA in EGFR-mutant NSCLC

## Summary
- FDA said substantial evidence of effectiveness is not established without a statistically significant overall survival benefit; PFS benefit alone failed to support a positive benefit-risk profile.
- HARMONi met its PFS primary endpoint, but the primary OS analysis showed only a positive trend that was not statistically significant.
- Post-hoc longer follow-up showed OS hazard ratio of 0.76 across the full, Asian and western patient populations.
- Safety: 16 patients (7.3%) discontinued ivonescimab for TRAEs vs 11 (5.0%) on placebo; treatment-related deaths 4 (1.8%) vs 5 (2.3%).
- Ivonescimab remains unapproved in the U.S. and Europe (China approval May 2024); Summit cites five positive Phase III studies and ongoing HARMONi-3, -7, -GI3, -GU1 trials.

## SEC filing metadata
- accession: 0001599298-26-000092
- form_type: 8-K
- ticker: SMMT
- cik: 0001599298
- company_name: Summit Therapeutics Inc.
- filed_at: 2026-11-16T11:08:15+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.92
- calibrated_materiality_score: 0.92
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1599298/000159929826000092/0001599298-26-000092-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1599298/000159929826000092/smmt-20261115.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001599298-26-000092
- JSON: https://secwatch.observer/filing/0001599298-26-000092.json
- Plain text: https://secwatch.observer/filing/0001599298-26-000092.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.
